Network Pharmacology and in vitro Experimental Verification on Intervention of Oridonin on Non-Small Cell Lung Cancer[J]. 中国结合医学杂志(英文版), 2025,31(4):347-356.
CHANG Ke, ZHU Li-fei, WU Ting-ting, et al. Network Pharmacology and in vitro Experimental Verification on Intervention of Oridonin on Non-Small Cell Lung Cancer[J]. Chinese journal of integrative medicine, 2025, 31(4): 347-356.
Network Pharmacology and in vitro Experimental Verification on Intervention of Oridonin on Non-Small Cell Lung Cancer[J]. 中国结合医学杂志(英文版), 2025,31(4):347-356. DOI: 10.1007/s11655-024-4116-7.
CHANG Ke, ZHU Li-fei, WU Ting-ting, et al. Network Pharmacology and in vitro Experimental Verification on Intervention of Oridonin on Non-Small Cell Lung Cancer[J]. Chinese journal of integrative medicine, 2025, 31(4): 347-356. DOI: 10.1007/s11655-024-4116-7.
Network Pharmacology and in vitro Experimental Verification on Intervention of Oridonin on Non-Small Cell Lung Cancer
摘要
Abstract
Objective:
2
To explore the key target molecules and potential mechanisms of oridonin against non-small cell lung cancer (NSCLC).
Methods:
2
The target molecules of oridonin were retrieved from Similarity Ensemble Approach (SEA)
Search Tool for Interacting Chemicals (STITCH)
SuperPred and TargetPred databases; target genes associated with the treatment of NSCLC were retrieved from GeneCards
DisGeNET and TTD databases. Then
the overlapping target molecules between the drug and the disease were identified. The protein–protein interaction (PPI) was constructed using the STRING database according to overlapping targets
and Cytoscape was used to screen for key targets. Molecular docking verification were performed using AutoDockTools and PyMOL software. Using the DAVID database
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were conducted. The impact of oridonin on the proliferation and apoptosis of NSCLC cells was assessed using cell counting kit-8
cell proliferation EdU image kit
and Annexin V-FITC/PI apoptosis kit respectively. Moreover
real-time quantitative PCR and Western blot were used to verify the potential mechanisms.
Results:
2
Fifty-six target molecules and 12 key target molecules of oridonin involved in NSCLC treatment were identified
including tumor protein 53 (TP53)
Caspase-3
signal transducer and activator of transcription 3 (STAT3)
mitogen-activated protein kinase kinase 8 (MAPK8)
and mammalian target of rapamycin (mTOR). Molecular docking showed that oridonin and its key target molecules bind spontaneously. GO and KEGG enrichment analyses revealed cancer
apoptosis
phosphoinosit
ide-3 kinase/protein kinase B (PI3K/Akt)
and other signaling pathways.
In vitro
experiments showed that oridonin inhibited the proliferation
induced apoptosis
downregulated the expression of Bcl-2 and Akt
and upregulated the expression of Caspase-3.
Conclusion:
2
Oridonin can act on multiple targets and pathways to exert its inhibitory effects on NSCLC
and its mechanism may be related to upregulating the expression of Caspase-3 and downregulating the expressions of Akt and Bcl-2.
Network Pharmacology Based Elucidation of Molecular Mechanisms of Laoke Formula for Treatment of Advanced Non-Small Cell Lung Cancer
Therapeutic Mechanism of Kai Xin San on Alzheimer's Disease Based on Network Pharmacology and Experimental Validation
Network Pharmacology-Based Exploration of Synergistic Mechanism of Guanxin Ⅱ Formula (冠心Ⅱ号方) for Coronary Heart Disease
Brucea javanica Seed Oil Emulsion and Shengmai Injections Improve Peripheral Microcirculation in Treatment of Gastric Cancer
Radix Sanguisorbae Improves Intestinal Barrier in Septic Rats via HIF-1α/HO-1/Fe2+ Axis
相关作者
FENG Yu-yu
LIU Jin-feng
XUE Yang
LIU Dan
WU Xiong-zhi
WANG Kan
YANG Rong
CHEN Tuan-tuan
相关机构
Department of Nursing, Tangshan Vocational and Technical College
School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine
Department of Oncology, Tianjin Medical University General Hospital
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for China
Tianjin Nankai Hospital, Tianjin Medical University